



NEONATAL MEDICATION PROTOCOLS

PALIVIZUMAB
 Created by: NCCU
 Date for review: Oct 2016

NCCU Clinical Guidelines
 KEMH/PMH
 Perth, Western Australia

DRUG:	PALIVIZUMAB
PRESENTATION:	Vial: 50mg powder (plus 1mL Water for Injection diluent) Vial :100mg powder (plus 1mL Water for Injection diluent)
ACTION & INDICATION:	Humanised IgG, anti RSV, monoclonal antibody. For immunoprophylaxis against severe RSV lower respiratory tract infections in high risk infants. May be used as “rescue” therapy for life threatening RSV infection.
DOSE:	15mg/kg/dose Repeat dose monthly during RSV season (usually May-October). Supplemental dose may be required following cardiac surgery.
PREPARATION:	Use solution provided by CIVAS or For 50mg vial: Add 0.6mL diluent provided to vial = 50mg in 0.5mL For 100mg vial: Add 1.0mL diluent provided to vial =100mg in 1mL Swirl gently. Do not shake or agitate the vial Let stand at room temperature for a minimum of 20 minutes until solution clears
ADMINISTRATION:	IM: In the anterolateral aspect of the thigh Give injection volumes > 1mL in divided doses
ADVERSE EFFECTS:	Induration and swelling at injection URTI, otitis media, fever, rhinitis, rash, cough, diarrhoea, wheeze Cyanosis, arrhythmia in patients with congenital heart disease. Rare: anaphylaxis and hypersensitivity reactions
COMMENTS:	Administer as soon as possible after dose is withdrawn from vial. Use contents of vial within 3hours of reconstitution Discard vial immediately after use
REFERENCES:	Neofax 2013
DATE:	October 2013